AstraZeneca PLC (AZN)vsCanadian Natural Resources Ltd (CNQ)
AZN
AstraZeneca PLC
$188.42
+2.74%
HEALTHCARE · Cap: $290.12B
CNQ
Canadian Natural Resources Ltd
$50.09
+2.92%
ENERGY · Cap: $101.52B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 52% more annual revenue ($58.74B vs $38.76B). CNQ leads profitability with a 27.9% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.50. CNQ earns a higher WallStSmart Score of 67/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
CNQ
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.7%
Fair Value
$305.60
Current Price
$188.42
$117.18 discount
Margin of Safety
+76.8%
Fair Value
$175.50
Current Price
$50.09
$125.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 150.0% year-over-year
Earnings expanding 372.3% YoY
Large-cap with strong market position
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CNQ
The strongest argument for CNQ centers on Revenue Growth, EPS Growth, Market Cap. Profitability is solid with margins at 27.9% and operating margin at 19.6%. Revenue growth of 150.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : CNQ
The primary concerns for CNQ are PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a value stock while CNQ is a growth play — different risk/reward profiles.
CNQ carries more volatility with a beta of 1.06 — expect wider price swings.
CNQ is growing revenue faster at 150.0% — sustainability is the question.
CNQ generates stronger free cash flow (2.3B), providing more financial flexibility.
Bottom Line
CNQ scores higher overall (67/100 vs 66/100), backed by strong 27.9% margins and 150.0% revenue growth. AZN offers better value entry with a 32.7% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Canadian Natural Resources Ltd
ENERGY · OIL & GAS E&P · USA
Canadian Natural Resources Limited acquires, explores, develops, produces, markets and sells crude oil, natural gas and natural gas liquids (NGL). The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?